A new analysis from the PREPARE (Pitavastatin to REduce Physical Function Impairment and FRailty in HIV) trial found that 52% of middle-aged adults with HIV experienced measurable declines in physical function over time. Published in the June 2025 issue of Open Forum Infectious Diseases, the study highlights the importance of identifying individuals at risk for functional decline to support aging with HIV and prevent disability.
The analysis included 569 participants with HIV (median age 51 years; interquartile range, 47–55), 81% of whom were male and 52% White. Physical function was assessed annually using gait speed, chair rise rate, grip strength, and a modified Short Physical Performance Battery (SPPB), which also included balance time. Decline was defined as falling below the 20th percentile on at least one measure. While overall declines were modest, variability among individuals was considerable.
Demographic and clinical risk factors for decline included female sex (RR, 1.32; 95% CI, 1.12–1.55), non-White race (RR, 1.23; 95% CI, 1.05–1.45), and older age. In multivariable analyses adjusting for age, sex, and race, additional independent predictors included history of depression treatment, elevated body mass index (BMI), baseline frailty, and elevated inflammatory markers such as high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).
To contextualize these findings, Contagion spoke with study authors Grace Kulik, PT, DPT, PhD candidate at the University of Colorado (UCD) Anschutz Medical Campus, and Kristine M Erlandson, MD, MS, professor of infectious diseases at UCD Anschutz about the clinical implications of functional decline in people with HIV (PWH), including the roles of inflammation, ART exposure, and screening in mitigating long-term impairment.